As SQSTM1 is a key regulator of NF-κB signaling, NF-κB inhibitors such as BAY 11–7082 may reduce SQSTM1-induced inflammatory cytokine release and chronic inflammation in IDD. This evidence concerns the gene NFKB1 and intervertebral disk degenerative disorder.